- Home
- PSHG vs JUNS Comparison
PSHG vs JUNS Comparison
Compare PSHG & JUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- JUNS
- Stock Information
- Founded
- PSHG 2010
- JUNS 2015
- Country
- PSHG Greece
- JUNS United States
- Employees
- PSHG N/A
- JUNS N/A
- Industry
- PSHG Marine Transportation
- JUNS
- Sector
- PSHG Consumer Discretionary
- JUNS
- Exchange
- PSHG Nasdaq
- JUNS NYSE
- Market Cap
- PSHG 20.8M
- JUNS 20.5M
- IPO Year
- PSHG N/A
- JUNS 2024
- Fundamental
- Price
- PSHG $1.72
- JUNS $1.19
- Analyst Decision
- PSHG Strong Buy
- JUNS
- Analyst Count
- PSHG 1
- JUNS 0
- Target Price
- PSHG $6.50
- JUNS N/A
- AVG Volume (30 Days)
- PSHG 191.8K
- JUNS 759.3K
- Earning Date
- PSHG 07-24-2025
- JUNS 08-11-2025
- Dividend Yield
- PSHG N/A
- JUNS N/A
- EPS Growth
- PSHG N/A
- JUNS N/A
- EPS
- PSHG 1.58
- JUNS N/A
- Revenue
- PSHG $86,407,000.00
- JUNS N/A
- Revenue This Year
- PSHG N/A
- JUNS N/A
- Revenue Next Year
- PSHG $23.25
- JUNS N/A
- P/E Ratio
- PSHG $1.08
- JUNS N/A
- Revenue Growth
- PSHG N/A
- JUNS N/A
- 52 Week Low
- PSHG $1.31
- JUNS $0.51
- 52 Week High
- PSHG $2.34
- JUNS $19.51
- Technical
- Relative Strength Index (RSI)
- PSHG 48.43
- JUNS N/A
- Support Level
- PSHG $1.75
- JUNS N/A
- Resistance Level
- PSHG $1.90
- JUNS N/A
- Average True Range (ATR)
- PSHG 0.15
- JUNS 0.00
- MACD
- PSHG -0.03
- JUNS 0.00
- Stochastic Oscillator
- PSHG 7.46
- JUNS 0.00
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.